Skip to content
FY'25FY'24FY'23FY'22
Profitability
Operating margin-512.9%+98,506pp-99,018.5%-17,984pp-81,035%-73,456pp-7,579.2%-4,888pp
Net margin-483.6%+88,904pp-89,387.1%-13,676pp-75,711.5%-68,382pp-7,329.2%-4,649pp
Returns
Return on equity-49.2%-0.7pp-48.5%+8.3pp-56.8%-12.2pp-44.6%+7.0pp
Return on invested capital-64.8%-0.9pp-63.9%+19.9pp-83.8%-15.3pp-68.6%+3.9pp
Efficiency
Asset turnover0.1×+0.1×0.0×0.0×0.0×
Liquidity
Current ratio12.6×-2.8×15.4×-2.8×18.3×+5.3×12.9×-1.7×
Leverage
Debt-to-equity0.1×0.0×0.0×0.0×0.0×
Valuation
Market capitalization$2.97B+95.6%$1.52B+32.6%$1.15B-2.6%$1.18B+174%
Price / sales41.9×-4,986×5,028.2×+1,381×3,647.5×+2,984×663.5×+519×
Price / book4.1×+1.9×2.3×-0.3×2.6×-0.4×+0.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Viridian Therapeutics, Inc.'s profit margins?
Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.
Where do Viridian Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.